https://www.selleckchem.com/pr....oducts/solcitinib.ht
47, P = 0.002), in contrast to those without CKD (hazard ratio 1.15, P = 0.21. The inclusion of any ECG-LVH parameters improved the accuracy of reclassification in any risk prediction model based on the eGFR, UACR, or Framingham 10-year risk score in the CKD participants (net reclassification improvement = 0.13-0.32, all P values less then 0.04. CONCLUSION In patients with CKD stage 1-5, ECG-LVH is useful for predicting the risk of future cardiovascular events and adds prognostic information to traditional cardiovascular risk ass
Like
Comment
Share
